Navigation Links
Neurobiological Technologies' CEO to Retire on December 31, 2008
Date:7/7/2008

EMERYVILLE, Calif., July 7 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII), today announced that Paul E. Freiman, president and chief executive officer (CEO), has announced his intent to retire on December 31, 2008. The Company expects Mr. Freiman to continue to serve on the Board. Mr. Freiman is the former chief executive officer of Syntex Corporation of Palo Alto, California.

Mr. Freiman is retiring after 11 years of service to the company. "Paul's strong leadership has helped grow our company to where we have a Phase 3 program in a highly underserved acute ischemic stroke market and his contributions with XERECEPT(R) and Memantine to our organization will be long- lasting. We thank him for his dedicated service and wish him the best as he moves on to the next chapter in his life," said Abraham E. Cohen, NTI's chairman of the Board of Directors.

Mr. Freiman stated, "Since I stepped into the role of an interim CEO in 1997, I have enjoyed all aspects of my time at NTI. I remain committed to our principal product, Viprinex(TM), which may provide an extraordinary opportunity in the treatment of acute ischemic stroke. I have announced my intent so that the Board of Directors has sufficient time to thoughtfully identify my successor. I will direct our operations with vigor over the next six months and continue to be an active NTI director beyond my retirement."

A committee has been formed by the Board of Directors, headed by NTI director, William A. Fletcher, Chairman of Teva North America, to search for a new CEO and has engaged the services of a retained search firm.

About Neurobiological Technologies, Inc.

Neurobiological Technologies, Inc, (Nasdaq: '/>"/>

SOURCE Neurobiological Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Neurobiological Technologies Reports Third Quarter Financial Results
2. Neurobiological Technologies Sets Date for Third Quarter Financial Results
3. Neurobiological Technologies Reports Receipt of $2.0 Million Royalty Payment for Quarterly Sales of Memantine
4. Neurobiological Technologies Appoints Matthew M. Loar as Chief Financial Officer
5. Neurobiological Technologies Announces Amendment of License and Cooperation Agreement with Merz Pharmaceuticals and Childrens Hospital
6. Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
7. Neurobiological Technologies Sets Date for Research and Development Day
8. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q2/08 Review Issued By Scimitar Equity Research, Inc.
9. Update: Neurobiological Technologies Sets Date for Second Quarter Financial Results and Conference Call
10. Neurobiological Technologies Sets Date for Second Quarter Financial Results
11. Neurobiological Technologies, Inc. Reports Retirement of Ronald E. Cape, Ph.D., from Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Colo. , May 23, 2013 Venaxis, ... diagnostic company focused on obtaining FDA clearance and commercializing ... today announced the pricing of an underwritten public offering ... warrants to purchase 3,500,000 shares of its common stock ... a combined public offering price of $1.25 per share ...
(Date:5/23/2013)... PuraMed BioScience ® , Inc., (OTCBB: ... (OTC) medicinal and healthcare products, announced that Ludlow ... based on low market capitalization valuation. ... Product to Treat Migraine Headaches , Clinical ... , Currently Available Nationwide at Walgreen,s and ...
(Date:5/23/2013)... , May 23, 2013  Saddleback Memorial Medical ... recently became the first hospital on the West Coast ... This new surgical option provides women with a state-of-the-art, ... Marc Winter , M.D., a highly ... surgeon and medical director of minimally invasive surgery at ...
(Date:5/23/2013)... 2013 Northwest Biotherapeutics (NASDAQ: NWBO ... personalized immune therapies for solid tumor cancers, announced ... year,s American Society Of Clinical Oncology (ASCO) meeting in ... role in immune therapy.  (Logo: http://photos.prnewswire.com/prnh/20110329/SF73084LOGO ... the pre-eminent conference focused on clinical treatment of cancer, ...
Breaking Biology Technology:Venaxis Announces Pricing of Offering of Common Stock and Warrants 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 3PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 2PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 3Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 2Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 3NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3
... Diamyd Medical AB,( http://www.omxgroup.com, ticker: DIAM B; ... Medical permission to start a Phase III,clinical study in ... therapeutic,diabetes vaccine Diamyd(R)., (Logo: http://www.newscom.com/cgi-bin/prnh/20080314/297194 ), ... to be able to offer this,promising drug to our ...
... ROCKVILLE, Md., March 14 Human Genome,Sciences, Inc. (Nasdaq: ... the,Cowen and Company 28th Annual Health Care Conference will ... ., (Logo: http://www.newscom.com/cgi-bin/prnh/20010612/HGSLOGO ), A ... present,a corporate overview on Wednesday, March 19, 2008 from ...
... March 14 Kosan Biosciences,Incorporated (Nasdaq: KOSN ... Vice President and Chief Financial Officer, will present ... Conference in Boston at the,Boston Marriott Copley Place ... Time. A live webcast of the presentation can ...
Cached Biology Technology:Diamyd Gets Authorization to Begin Phase III Study in the US 2Kosan Biosciences to Present at the Cowen and Company 28th Annual Health Care Conference 2
(Date:5/24/2013)... the world,s largest and fastest growing open-access publishers, today ... in Physics . , A broad scope journal covering ... an open-science and interactive web platform for the research ... , Frontiers, real-time and interactive peer-review enables fast, ... types. With an average of three months from submission ...
(Date:5/24/2013)... have focused among other factors on drugs that ... the accumulation of A-beta that causes the known plaques in ... of A-beta is APP. Alessia Soldano and Bassem Hassan (VIB/KU ... the fruit-fly version of APP in the brain ... "We have discovered that APPL ensures that brain cells form ...
(Date:5/23/2013)... 284 million tons of cargo, transit the Panama Canal each ... the Panama Canal Authority. Each time a ship passes through, ... Gatun Lake, which is also a source of water for ... However, the advent of very large "super" cargo ships, now ... demanded change. The Panama Canal is being expanded to create ...
Breaking Biology News(10 mins):Frontiers launches new open-access journal in physics 2Frontiers launches new open-access journal in physics 3A new strategy required in the search for Alzheimer's drugs? 2Reforestation study shows trade-offs between water, carbon and timber 2Reforestation study shows trade-offs between water, carbon and timber 3
... the human genome sequence annotation, high-throughput cloning methodologies, ... of Proteomics lead by Leonardo Brizuela (Harvard Medical ... mined public databases to collect the sequence information ... built a gene repository for this gene class. ...
... sake of five others may be the way to go ... building, but a Penn State Erie biologist is monitoring the ... animals and insects. , "I am currently doing research in ... wetlands to replace all the ones that were destroyed by ...
... suspected that fertilizer runoff from big farms can trigger ... ecosystems and even producing "dead zones" in the sea. ... the first direct evidence linking large-scale coastal farming to ... the March 10 issue of the journal Nature, the ...
Cached Biology News:Road salt affects mitigation wetlands 2Oceans more vulnerable to agricultural runoff than previously thought, study finds 2Oceans more vulnerable to agricultural runoff than previously thought, study finds 3Oceans more vulnerable to agricultural runoff than previously thought, study finds 4
... for determination of baculovirus titers in just 2448 ... methods. Classical determination of baculovirus titer has relied ... Kit takes advantage of the appearance of detectable ... surface as early as 824 hours post-infection. Detection ...
...
... Silica Bead Kit has been designed for recovery of ... Features Ultra fast protocol: DNA ... silica beads are easy to resuspend Bead uniformity ... pure DNA (suitable for PCR) DNA is eluted ...
... BAS-2500 is ideal for ... Biology (1D electrophoresis, 2D ... Macroarrays); Pharmacokinetics & Toxicology ... layer chromatography); Physical and ...
Biology Products: